AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00918632 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AG-013736
Description: A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -> A -> B. Each of these treatments will be separated by a 7 day washout period.
Study NCT00918632 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AG-013736
Description: A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -> B -> A. Each of these treatments will be separated by a 7 day washout period.
Study NCT02094352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Group + Epidural infusion
Description: The saline and epidural infusions will be administered over 96 hours with appropriate titration.
Study NCT02094352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Booster Infusion
Description: Patients will receive three ketamine booster infusions over the course of three months.
Study NCT02094352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Group Booster Infusion
Description: Patients will receive three saline booster infusions over the course of three months.
Study NCT03558425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-381
Description: 1 tablet administered before the breakfast during 7 days
Study NCT03558425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D026
Description: 1 tablet administered before the breakfast during 7 days
Study NCT02857725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 987517
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Study NCT02857725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 15 Control
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Study NCT04100980 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study NCT01946620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutiform
Study NCT01946620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Study NCT01058642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5747
Study NCT01058642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01058642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01058642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT04201548 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance Training
Description: These patients will perform an aerobic exercise with a moderate intensity cycle ergometer. The exercise session on an exercise bike will last 33 minutes at a constant load, starting from an intensity equal to the load of 60% of the maximum load (max watt) achieved at the incremental test.~Working volume = 60 X 33 = 1980
Study NCT04201548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long High Intensity Interval Training
Description: The patients assigned to the Long-HIIT group will perform a 32-minute interval work with 4x4 protocol (active phase x passive phase) performing 4 minutes at an intensity of 80-85% of the Max Watt (active phase) spaced from 4 minutes to 40% of the Max Watt (passive phase). The goal of high intensity work will be to bring the heart rate to a level close to 85-90% of the maximum cardiac frequency achieved in the incremental exercise test. If this target is not reached within the session, the load of the next one will be increased in the following session with 10 watt steps.~Working volume = 16 X 85 + 16 x 40 = 2000
Study NCT04201548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short High Intensity Interval Training
Description: The patients assigned to the Short-HIIT group will perform an interval work with initial intensity equal to 100% of the Max Watt highlighted in the incremental exercise stress test in the phase (30 seconds) followed by a passive phase of 30 seconds at 50% of the Max Watt for a period of 26 minutes a day. The intensity will be gradually increased during the sessions with symptom-based progression, according to the protocol of Maltais et al. with steps of 10 watts each increment.~Working volume = 13 X 100 + 13 x 50 = 2050
Study NCT02023385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-9000 LLLT
Description: Irradiation of adipocyte cells within the fat layer with BTL-9000 LLLT for the release of fat and lipids from these cells
Study NCT02023385 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham BTL-9000 LLLT
Description: Irradiation of adipocyte cells within the fat layer with sham BTL-9000 LLLT for the release of fat and lipids from these cells
Study NCT02917616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alkaline drinking-water
Study NCT02917616 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neutral drinking-water
Study NCT05006183 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: Percutaneous coronary intervention with Drug-Eluting Stents
Study NCT05006183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: Percutaneous coronary intervention with Drug-Eluting Stents
Study NCT00566098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MILs
Study NCT00566098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study NCT00566098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Study NCT02023502 — intervention group
Intervention type: OTHER
Intervention: collection of urine and blood sample
Study NCT01676584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6811135
Description: single ascending doses sc
Study NCT01676584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single doses sc
Study NCT03183271 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam proton radiation therapy.
Description: Treatment of irradiation with protons beam The patients will be enrolled either at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy, or at referral Hospitals enrolling head and neck patients for treatment with photon IMRT.
Study NCT04137991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nol-Index guided analgesia
Description: Monitor that indicates the level of nociception-antinociception balance
Study NCT04137991 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Analgesia
Description: Administration of remifentanil based guided by heart rate, blood pressure, and experience
Study NCT02122159 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MA09-hRPE Cellular Therapy
Description: A suspension of either 50,000 MA09-hRPE cells (first cohort), 100,000 MA09-hRPE cells (second cohort), 150,000 MA09-hRPE cells (third cohort) or 200,000 MA09-hRPE cells (fourth cohort) in 150 uL of BSS plus will be implanted over 1 minute in the space created.
Study NCT00475852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: 0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
Study NCT00475852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
Study NCT01197222 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndoClear Lens Cleaning Device
Description: EndoClear Lens Cleaning Device is used during a laparoscopic abdominal surgery.
Study NCT01973127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verum rTMS
Description: rTMS on the right dorsolateral prefrontal cortex. TMS procedure: The resting motor threshold (RMT) will be defined in each subject as the minimal stimulation intensity evoking an MEP of ≥ 0.05 mV in 50% of the trials in the muscle of the right thumb (M. abductor pollicis brevis). TMS will be conducted in the form of 'conventional rTMS', whereby 30 trains of 10 Hz pulses with a duration of 5 seconds and an inter-train interval of 25 seconds are applied to the righ dorsolateral prefrontal cortex (50 pulses per train, 6000 pulses per session). Used equipment: Magstim Rapid 2 device.
Study NCT01973127 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: TMS procedure: The resting motor threshold (RMT) will be defined in each subject as the minimal stimulation intensity evoking an MEP of ≥ 0.05 mV in 50% of the trials in the muscle of the right thumb (M. abductor pollicis brevis). Like in verum TMS coil will be placed on the skull, but no magnetic field will be pulsed. Used equipment: Magstim Rapid 2 device.
Study NCT02699177 — intervention group
Intervention type: DEVICE
Intervention: CBF measurements
Description: CBF measurements
Study NCT02654080 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 nef/tat/vif, env pDNA vaccine
Description: 1500 mcg to be administered as 0.5 mL intramuscular (IM) in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device
Study NCT02654080 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVSV HIV envC vaccine
Description: 1 × 10\^7 PFU to be administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)
Study NCT02654080 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride for Injection, USP 0.9%;~At Months 0, 1, and 3: administered as 0.5 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device.~At Months 6 and 9: administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated).
Study NCT03036722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flaxseed
Description: Flaxseed is a member of the genus Linum in the family Linaceae. It is a food and fiber crop and it occurs in two basic varieties: brown and yellow or golden (also known as golden linseeds).
Study NCT03036722 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control porridge
Description: control porridge matched for energy and fat content.
Study NCT03984734 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatoduodenectomy with antrectomy
Study NCT03984734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pylorus-preserving pancreatoduodenectomy
Study NCT00104845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human gp100 plasmid DNA vaccine
Study NCT00104845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mouse gp100 plasmid DNA vaccine
Study NCT01879735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-CSar
Description: PET/CT recording with bile acid tracer 11C-cholylsarcosine used to evaluate the transport of bile acids.
Study NCT01879735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG
Description: Infusion of indocyanine green prior and during the PET/CT scanning with the bile tracer 11C-CSar.
Study NCT04643496 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic or open Ileocolic resection
Description: Laparoscopic or open Ileocolic resection
Study NCT01058642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Study NCT01286467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: Escalating dose of PF-04449913 administered as tablets PO QD in 28-day cycles
Study NCT04114929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Threshold-based Training
Description: Specific ventilatory markers determined from a cardiopulmonary test and the correlating heart rate will be used to determine exercise intensity
Study NCT04114929 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Using the standard care cardiac rehabilitation guidelines exercise will be based on estimated heart rate maximum followed by the karvonan method to calculate 40-70% heart rate reserve
Study NCT00514215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: 250 μg, inhaled, two times a day, on days 4-10 and days 36-42
Study NCT00514215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Days 1 \& 32
Study NCT02848508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT01032681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD 521873
Description: Dose escalation steps:~Group 1: 0,075mg/kg - 0,15mg/kg - 0,225mg/kg - 0,3mg/kg - 0,45mg/kg - 0,6mg/kg - 0,9mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle
Study NCT01032681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD 521873
Description: Dose escalation steps:~Group 2: CPA plus 0,6mg/kg - 0,9mg/kg~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle
Study NCT01032681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD 521873
Description: Dose escalation steps:~Group 3: 0,9mg/kg - 1,2mg/kg - 1,5mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle
Study NCT03574883 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tACS
Description: tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
Study NCT03574883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS
Description: tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
Study NCT03574883 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tACS
Description: tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
Study NCT03574883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
Study NCT03574883 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
Study NCT01170260 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: INFORMATION-ONLY SEXUAL RISK REDUCTION (INFO-ONLY)
Description: Intervention includes presentation of STD facts, safe sex activities, condom demonstration, video about sexual decision making, group discussion
Study NCT01170260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEXUAL PLUS ALCOHOL RISK REDUCTION (SRRI+ETOH)
Description: Intervention includes presentation of STD/alcohol facts, safe sex activities, condom demonstration, video about alcohol/sexual decision making, group discussion
Study NCT01170260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEXUAL + ALCOHOL + MARIJUANA RISK REDUCTION
Description: Intervention includes presentation of STD/alcohol/marijuana facts, safe sex activities, condom demonstration, video about alcohol/marijuana/sexual decision making, group discussion
Study NCT02614703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy using Acetic Acid 2.5%
Description: Spraying esophageal mucosa during random biopsies for Barrett's esophagus
Study NCT02614703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard random esophageal biopsies
Description: Random esophageal biopsies performed as per protocol
Study NCT02931565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olinciguat
Description: oral tablet
Study NCT02931565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: oral tablet
Study NCT00851266 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V512
Description: Subjects received 1 of 8 formulations of the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6:~1) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 2) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 3) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 4) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 5) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX; 6) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 7) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 8) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX;
Study NCT00851266 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to V512
Description: Subjects received placebo to the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6.
Study NCT02382471 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: 4 cap 1 g Omega-3 per day for 2 months
Study NCT02382471 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 cap 1 g Placebo(paraffin) per day for 2 months
Study NCT03198637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium's monitoring by TOF (train-of-four) WATCH device.
Description: Neuromuscular blockade's monitoring by Cisatracurium thanks to TOF (train-of-four) WATCH device.
Study NCT03198637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clinical assessment
Study NCT00635388 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: oral, placebo, once/day for 12 weeks
Study NCT00635388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus (Probiotic 1)
Description: oral, Lactobacillus, once/day for 12 weeks
Study NCT00635388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus and Bifidobacterium (Probiotic 2)
Description: oral, Lactobacillus and Bifidobacterium, once/day for 12 weeks
Study NCT02872181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supine
Description: Placed in Supine position
Study NCT02872181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left uterine displacement
Description: Placed in 15 degrees left uterine displacement
Study NCT02012205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wet cupping
Description: Participants assigned to the treatment group will receive wet-cupping therapy 3 times per week for 2 weeks
Study NCT02005354 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Trans-cutaneous Electrical Nerve Stimulation (TENS)
Description: Patients in whom a bone marrow biopsy is planned will be randomised to one of two groups - a Placebo Comparator group where the TENS machine will be set at the lowest sensory threshold and an Active Comparator group where the TENS machine will be set at a recognised analgesic level (>50Hz and below the pain threshold for the patient).
Study NCT02005354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-cutaneous Electrical Nerve Stimulation (TENS)
Description: Patients in whom a bone marrow biopsy is planned will be randomised to one of two groups - a Placebo Comparator group where the TENS machine will be set at the lowest sensory threshold and an Active Comparator group where the TENS machine will be set at a recognised analgesic level (>50Hz and below the pain threshold for the patient).
Study NCT02005354 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)
Description: All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)
Study NCT02005354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)
Description: All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)